A Phase 1, First in Human Study of CTIM-76, a Claudin-6 (CLDN6)-Directed Bispecific Antibody, in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 04 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CTIM 76 (Primary)
Indications Endometrial cancer; Gynaecological cancer; Ovarian cancer; Testicular cancer
Focus Adverse reactions; First in man

14 Jan 2025 According to Context Therapeutics media release, first patient had been dosed in this trial, The Company anticipates sharing initial data for the CTIM-76 Phase 1 trial in the first half of 2026.
16 Oct 2024 According to Context Therapeutics media release, company announced a poster regarding the CTIM-76, from this trial will be presented at the Society for Immunotherapy of Cancers (SITC) 39th Annual Meeting, being held November 8-10, 2024 at the George R. Brown Convention Center in Houston, TX.
07 Aug 2024 According to Context Therapeutics media release, first patient dosing expected in third quarter of 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com